Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

PHASE2CompletedINTERVENTIONAL

Enrollment

222

Participants

Timeline

Start Date

February 1, 2016

Primary Completion Date

July 25, 2016

Study Completion Date

July 25, 2016

Conditions

Attention-Deficit/Hyperactivity Disorder (ADHD)

Interventions

DRUG

Placebo

Placebo was administered once daily

DRUG

100mg SPN-812

100mg SPN-812 was administered once daily and compared to placebo

DRUG

200mg SPN-812

200mg SPN-812 was administered once daily and compared to placebo

DRUG

300mg SPN-812

300mg SPN-812 was administered once daily and compared to placebo

DRUG

400mg SPN-812

400mg SPN-812 was administered once daily and compared to placebo

Trial Locations (1)

Florida Clinical Research Center, LLC, Maitland

All Listed Sponsors

lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT02633527 - Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD | Biotech Hunter | Biotech Hunter